FOLD

News

seekingalpha.comBioMarin: 'Strong Buy' On VOXZOGO Expansion And Amicus Acquisitionseekingalpha.comMay 6

fool.comCIBRA Capital Makes a Big Merger Arbitrage Bet On Amicus Therapeutics (FOLD)fool.comApr 25

seekingalpha.comBioMarin Pharmaceutical's Rare Disease Portfolio Supplemented By Amicus Acquisition Makes A Buyseekingalpha.comApr 15

defenseworld.netSG Americas Securities LLC Acquires 36,938 Shares of Amicus Therapeutics, Inc. $FOLDdefenseworld.netApr 7

defenseworld.netCapricorn Fund Managers Ltd Invests $3 Million in Amicus Therapeutics, Inc. $FOLDdefenseworld.netApr 6

Trade FOLD

About Amicus Therapeutics, Inc.

Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery, development, and delivery of medical treatments for rare conditions. Its primary commercial offering is Galafold, an orally administered precision medicine designed for adult patients with a confirmed diagnosis of Fabry disease, specifically those exhibiting an amenable galactosidase alpha gene variant as identified by in vitro assay data. The company's pipeline also includes several investigational therapies: AT-GAA, an innovative treatment strategy for Pompe disease; various enzyme replacement therapies aimed at Pompe diseases; and AT-GTX-502, an AAV serotype gene therapy for CLN3. The latter is currently undergoing Phase 1/2 clinical studies to evaluate the safety and efficacy of a single intrathecal administration in patients with CLN3. Additionally, Amicus is exploring therapeutic approaches related to CDKL5, a gene on the X-chromosome that encodes a protein essential for regulating proper brain development. Amicus maintains strategic collaborations and licensing arrangements with prominent entities such as Nationwide Children's Hospital, the University of Pennsylvania, and GlaxoSmithKline. The company was founded in 2002 and is based in Philadelphia, Pennsylvania.

CEO: Bradley L. Campbell
IPO Date: May 31, 2007

Market Data

Open: $14.49
High: $14.49
Low: $14.49
Volume: 0
Avg Volume: 4.2M
52W High: $14.50
52W Low: $5.51

Valuation

Market Cap: $4.5B
Enterprise Value: $4.8B
Dividend Yield: 0.00%

Financials

Free Cash Flow: $30M
Revenue: $634M
Net Income: $-27M
Cash: $214M
Debt: $483M

Events

EarningsMay 7

EPS est. 0.04667